(Circulation. 1999;100:1917-1922.)
© 1999 American Heart Association, Inc.
Basic Science Reports |
From the Departments of Pharmacology, Laboratory Animal Medicine, Pharmaceutical Research and Development, and Medicinal Chemistry, Merck Research Laboratories, West Point, Pa, and the Department of Physiology, The Ohio State University, Columbus.
Correspondence to Dr Joseph J. Lynch, Jr, WP46-300, Merck Research Laboratories, West Point, PA 19486.
BackgroundTo date, the lack of potent and selective inhibitors has hampered the physiological assessment of modulation of the cardiac slowly activating delayed rectifier current, IKs. The present study, using the IKs blocker L-768,673, represents the first in vivo assessment of the cardiac electrophysiological and antiarrhythmic effects of selective IKs blockade.
Methods and ResultsIn an anesthetized canine model of recent (8.5±0.4 days) anterior myocardial infarction, 0.003 to 0.03 mg/kg L-768,673 IV significantly suppressed electrically induced ventricular tachyarrhythmias and reduced the incidence of lethal arrhythmias precipitated by acute, thrombotically induced posterolateral myocardial ischemia. Antiarrhythmic protection afforded by L-768,673 was accompanied by modest 7% to 10% increases in noninfarct zone ventricular effective refractory period, 3% to 5% increases in infarct zone ventricular effective refractory period, and 4% to 6% increases in QTc interval. In a conscious canine model of healed (3 to 4 weeks) anterior myocardial infarction, ventricular fibrillation was provoked by transient occlusion of the left circumflex coronary artery during submaximal exercise. Pretreatment with 0.03 mg/kg L-768,673 IV elicited a modest 7% increase in QTc, prevented ventricular fibrillation in 5 of 6 animals, and suppressed arrhythmias in 2 additional animals.
ConclusionsThe present findings suggest that selective blockade of IKs may be a potentially useful intervention for the prevention of malignant ischemic ventricular arrhythmias.
Key Words: antiarrhythmia agents arrhythmia myocardial infarction fibrillation
This article has been cited by other articles:
![]() |
P. G.A. Volders, M. Stengl, J. M. van Opstal, U. Gerlach, R. L.H.M.G. Spatjens, J. D.M. Beekman, K. R. Sipido, and M. A. Vos Probing the Contribution of IKs to Canine Ventricular Repolarization: Key Role for {beta}-Adrenergic Receptor Stimulation Circulation, June 3, 2003; 107(21): 2753 - 2760. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Lynch Jr., J. J. Salata, A. A. Wallace, G. L. Stump, D. B. Gilberto, H. Jahansouz, N. J. Liverton, H. G. Selnick, and D. A. Claremon Antiarrhythmic Efficacy of Combined IKs and beta -Adrenergic Receptor Blockade J. Pharmacol. Exp. Ther., July 1, 2002; 302(1): 283 - 289. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kang, X.-L. Chen, L. Wang, and D. Rampe Interactions of the Antimalarial Drug Mefloquine with the Human Cardiac Potassium Channels KvLQT1/minK and HERG J. Pharmacol. Exp. Ther., October 1, 2001; 299(1): 290 - 296. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Xu, S. J. Rials, Y. Wu, J. J. Salata, T. Liu, D. B. Bharucha, R. A. Marinchak, and P. R. Kowey Left Ventricular Hypertrophy Decreases Slowly but Not Rapidly Activating Delayed Rectifier Potassium Currents of Epicardial and Endocardial Myocytes in Rabbits Circulation, March 20, 2001; 103(11): 1585 - 1590. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |